Maxim Group restated their buy rating on shares of Biopharmx (NYSEAMERICAN:BPMX) in a report issued on Friday morning. The firm currently has a $1.50 price objective on the biotechnology company’s stock.

“BPMX reported mixed F3Q18 (Oct) results. Revenue of $18,000, down 45.5% y/y, was above our estimate of $9,100, but below consensus of $20,000. GAAP EPS of ($0.05), compared to ($0.12) in F3Q17, was narrower than our estimate of ($0.06) and inline with consensus of ($0.05). The company also received positive feedback from the FDA on the design of its planned phase 3 clinical trial of BPX-01 for acne. As of October 31, 2017, cash and cash equivalents were $1.6M. On November 24, 2017, BPMX completed an $11M public offering that is expected to fund a phase 2 rosacea trial.”,” Maxim Group’s analyst wrote.

Separately, HC Wainwright reaffirmed a buy rating and set a $3.00 price target on shares of Biopharmx in a research report on Tuesday, September 19th.

Shares of Biopharmx (NYSEAMERICAN:BPMX) opened at $0.12 on Friday. Biopharmx has a 52 week low of $0.11 and a 52 week high of $0.90.

Biopharmx (NYSEAMERICAN:BPMX) last issued its quarterly earnings data on Wednesday, September 13th. The biotechnology company reported ($0.06) EPS for the quarter, hitting the consensus estimate of ($0.06). The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.02 million. Biopharmx had a negative return on equity of 5,749.08% and a negative net margin of 22,005.88%.

In related news, Director Stephen Morlock purchased 330,000 shares of the business’s stock in a transaction dated Friday, November 24th. The stock was purchased at an average cost of $0.15 per share, with a total value of $49,500.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Vivo Capital Viii, Llc sold 296,394 shares of the firm’s stock in a transaction on Thursday, November 9th. The stock was sold at an average price of $0.20, for a total value of $59,278.80. The disclosure for this sale can be found here.

COPYRIGHT VIOLATION NOTICE: “Biopharmx (BPMX) Earns “Buy” Rating from Maxim Group” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.thecerbatgem.com/2017/12/11/biopharmx-bpmx-earns-buy-rating-from-maxim-group.html.

About Biopharmx

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Receive News & Stock Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related stocks with our FREE daily email newsletter.